[Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].

Area of Science:

• Immunotherapy
• Oncology
• Cellular Engineering

Background:

• Multiple myeloma is a cancer of plasma cells.
• B-cell maturation antigen (BCMA) is a target expressed on myeloma cells.
• Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in hematologic malignancies.

Purpose of the Study:

• To construct a BCMA-specific CAR using the APRIL ligand as the antigen-binding region.
• To evaluate the anti-myeloma activity of BCMA-CAR-T cells in vitro and in vivo.

Main Methods:

• BCMA-CAR construct designed with APRIL ligand and 4-1BB costimulatory domain.
• In vitro cytotoxicity assays against BCMA-positive myeloma cell lines and primary cells.
• In vivo anti-tumor efficacy assessment in a human BCMA-positive myeloma xenograft mouse model.

Main Results:

• BCMA-CAR-T cells demonstrated specific killing of BCMA-positive myeloma cells and primary multiple myeloma cells.
• Significant degranulation and cytokine release observed in vitro.
• BCMA-CAR-T cell therapy significantly prolonged survival in a myeloma xenograft mouse model.

Conclusions:

• Ligand-based BCMA-CAR-T cells are a potential therapeutic strategy for BCMA-positive multiple myeloma.
• This approach offers a novel way to target myeloma cells effectively.